Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Aurinia Pharmaceuticals is a commercial-stage biotech whose economics are centered on LUPKYNIS (voclosporin), the first FDA-approved oral treatment for adult active lupus nephritis, with U.S. sales supplemented by Otsuka licensing and royalties abroad. Its differentiation includes rapid proteinuria reduction, dual immune and podocyte effects, and no routine therapeutic drug monitoring; the AURORA study reported a 53% reduction in renal-related events or mortality versus standard therapy alone. Q2 2026 revenue rose 19% to $83.2 million, LUPKYNIS sales rose 19% to $79.4 million, and GAAP net income increased 74% to $37.4 million. Gross margin was approximately 92%, operating cash flow was $52.5 million for the quarter, and cash and investments totaled $443.1 million with no long-term debt reported. Management reaffirmed FY2026 revenue guidance of $315–$325 million and product sales of $305–$315 million. **The Teva settlement supports U.S. generic protection through December 2036**, while below-8% estimated U.S. patient penetration leaves room to grow. At $16.02, the report sees attractive valuation and a $31.97 probability-weighted five-year price target, with near-term catalysts in PRESERVE and pipeline development balanced against product concentration and pending generic litigation.